Background: Atazanavir (300 mg) boosted by ritonavir (100 mg) is the preferred third drug in pregnancy. However, there is still discordance on atazanavir dose increase during the third trimester.
Introduction
Combined ART has profoundly reduced morbidity and mortality of HIV-infected patients; it has also dramatically reduced the vertical transmission of HIV. 1 Pharmacokinetic studies on PIs have shown a decrease in these compounds' systemic exposure (particularly in the third trimester) in pregnant HIV-positive subjects thus increasing the risk of virological failure. [2] [3] [4] Some studies showed lower atazanavir concentrations during pregnancy if compared with postpartum, 5, 6 whereas others did not report significant differences. 7, 8 Although antiretroviral drug targets are the infected cells, only few studies analysed the intracellular concentration and none was conducted in pregnant individuals. 9 Therefore, we designed a prospective study to evaluate atazanavir and ritonavir standard-dose plasma and intracellular concentrations during pregnancy and the post-partum period.
Methods

Patients
HIV-infected pregnant patients on atazanavir/ritonavir-based ART (300/100 mg once daily) had prospectively been enrolled at the outpatient Clinic of the Infectious and Tropical Diseases Unit, University of Brescia (Brescia, Italy).
Blood sampling was undertaken in the first, second and third trimesters and in the post-partum period (12-14 weeks after delivery).
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Data on HIV status of newborns (up to 6 months of life), time of delivery (preterm delivery was defined as ,37 weeks) and weight at birth (low birth weight was defined as ,2500 g) were collected.
Pharmacokinetics
All pharmacokinetic analyses were performed at the Laboratory of Pharmacokinetics of the University of Torino (Torino, Italy). Atazanavir and ritonavir PBMC-associated and plasma concentrations were measured by validated HPLC-MS and HPLC-photodiode array methods, respectively. 10, 11 PBMCs were isolated and the cell number and mean cellular volume were determined using a Coulter counter. Blood samples were collected 24+3 h after drug intake (as reported by patients), to evaluate trough concentrations (C trough ).
The predetermined atazanavir minimum effective concentration was 150 ng/mL. 12 
Statistical analysis
For descriptive statistics, continuous variables were described as median (IQR) and categorical variables as frequency (percentage). Variables were tested using non-parametric methods (Spearman's, Fisher's, Mann-Whitney); paired comparisons between plasma and intracellular concentrations over timepoints were performed through Wilcoxon's and McNemar's tests. Statistical analyses were performed using the SPSS software package version 18.0 (Chicago, IL, USA), accepting statistical significance at P 0.05.
While planning a study of a continuous variable response from matched pairs, we considered as prior data showing a normally distributed difference with a standard deviation of 0.25. Considering a true difference of 0.2, a sample size of 18 pairs of subjects was suggested as an appropriate estimate (null hypothesis probability of 0.9). The Type I error probability associated with this test of this null hypothesis is 0.05. We considered a no show/drop rate of 25% and thus planned to enrol 25 subjects.
Ethics
The local Ethics Committee of Brescia Province (Italy) approved the study protocol on 3 September 2013. Each patient signed a written informed consent form before any study procedures started. The study was conducted in accordance with the Helsinki Declaration and with the Good Clinical Practice rules.
Results
Patient enrolment
Twenty-five HIV-infected pregnant women were enrolled from November 2013 to January 2016. Thirteen patients in the first trimester of pregnancy (1-13.1 weeks), nine in the second (13.2-26.2 weeks) and three in the third (26.3-40 weeks) took part in the study. Three of the 13 patients enrolled during the first trimester of pregnancy had a spontaneous abortion; for these patients pharmacokinetic sampling was not performed. One patient withdrew her consent during the second trimester. Two patients, enrolled in the second trimester, were lost to follow-up during the third trimester. Scheduled blood sampling was available in 10 (first trimester), 17 (second trimester), 18 (third trimester) and 19 (12 weeks post-partum) patients.
Patient characteristics
At the time of inclusion, the median age was 32 years (IQR " 27-35). Thirteen patients (52%) were Caucasians and 12 (48%) were black Africans. Concomitant tenofovir/emtricitabine was used in 21 patients (84%), while abacavir/lamivudine was used in 4 subjects.
Viroimmunological outcomes
The median CD4! T lymphocyte count was 736 cells/mm At study baseline all patients had plasma HIV RNA ,37 copies/mL. At the time of delivery, maternal HIV RNA ,37 copies/mL was maintained in all patients. We observed two virological blips in the post-partum period (130 and 150 copies/mL) due to incomplete adherence: 1 month later HIV RNA was undetectable in both subjects and atazanavir concentrations were within the expected range (both in plasma and in PBMCs).
Clinical outcomes
Fourteen infants (14 of 19; 74%) were delivered by caesarean section (one was an emergency caesarean because of premature rupture of membranes), while the remaining five were given birth by vaginal delivery. All newborns were HIV negative at delivery and up to 6 months; low birth weight was recorded in five newborns (26%), while preterm birth was observed in four (21%). Neither congenital abnormalities nor other clinical conditions were observed.
Pharmacokinetic results
Despite the fact that atazanavir plasma concentrations (Figure 1a) showed a trend to decrease in the second and third trimesters compared with the post-partum period (P " 0.033 and P " 0.030, respectively), intracellular atazanavir concentrations (Figure 1b) showed non-significant changes over time (P . 0.05). Conversely, plasma (second and third trimesters compared with post-partum; P " 0.017 and P " 0.033, respectively) and intracellular (second trimester compared with third trimester; P " 0.008) ritonavir concentrations were lower during pregnancy (Figure 2) . Moreover, comparing data between the first trimester and other trimesters as well as between the first trimester and the post-partum period we found no significant difference (P . 0.05).
In addition, atazanavir intracellular/plasma concentration ratios were 1.32 (IQR " 0.98-2.77) during the first trimester, 1.34 (IQR " 1.13-1.88) during the second trimester, 1.38 (IQR " 0.61-2.63) during the third trimester and 1.07 (IQR " 0.56-2.69) during the post-partum period. These differences were not statistically significant (P . 0.05). Ritonavir intracellular/plasma ratios were 19.77 (IQR " 9.5-52.8), 27.72 (IQR " 17.64-41.73), 23.7 (IQR " 13.03-54.28) and 12.98 (IQR " 6.32-19.08) in the first, second and third trimesters and post-partum and were higher between both the second and third trimesters in respect of post-partum (P " 0.016 and P " 0.015, respectively). Only one participant (4%) per each trimester and two participants (8%) in the post-partum period had atazanavir trough concentrations ,150 ng/mL. No differences were found (P . 0.05) according to ethnicity (Caucasians versus black Africans).
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Discussion
This was the first study evaluating the intracellular pharmacokinetics of atazanavir during pregnancy. It shows that concentrations of standard-dose boosted atazanavir remain stable during pregnancy with no significant differences versus post-partum. Treatment efficacy and positive pregnancy outcomes were also observed.
The first study in pregnancy on 300/100 mg atazanavir/ritonavir during the third trimester and after birth concluded that an increase in the atazanavir dose is not necessary. 7 Two other studies confirm these results. 8, 13 Eventually, two studies on HIVinfected pregnant patients, receiving 300/100 mg atazanavir/ritonavir increased to 400/100 mg in the third trimester, revealed that an increase in the atazanavir/ritonavir dosing may be useful both in the third and in the second trimester of pregnancy. 14, 15 Nonetheless, the majority of these studies show that the standard boosted atazanavir dose provides adequate plasma concentrations throughout pregnancy maintaining a satisfactory Intracellular atazanavir/ritonavir in pregnancy JAC antiviral efficacy. Therefore, the use of unboosted atazanavir is not recommended. 16 Our results are similar to those studies that did not recommend an increase in the atazanavir dose during pregnancy. 5, 7, 8 According to ethnicity, a balanced distribution of women enrolled (52% Caucasians and 48% black Africans) was observed, as a non-significant difference in terms of pharmacokinetic parameters was recorded.
The intracellular/plasma ratio increased during pregnancy without significant variations. It is also noteworthy that atazanavir is the PI with the highest level of intracellular accumulation. 11, 17 This study also showed some limitations such as the limited sample size in the first trimester, the small number of patients receiving abacavir/lamivudine and the variability in intracellular concentrations (PBMC separation was performed manually thus generating possible differences between operators). In addition, PBMCs may not be representative of other body tissues where the expected penetration could be different.
In conclusion, this study shows that atazanavir intracellular concentrations remain stable during pregnancy despite a trend to decreased atazanavir and ritonavir plasma concentrations. Our data support the efficacy and tolerability of boosted atazanavir standard dose in pregnant HIV-infected women.
